-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 13, Zhejiang Haizheng Pharmaceutical Co., Ltd. and Suzhou Xuanjing Biotechnology Co., Ltd. and its wholly-owned subsidiary Beijing Xuanjingrui Pharmaceutical Technology Co., Ltd. formally signed a small nucleic acid licensing cooperation agreement. Dazzling Biotech granted Haizheng Pharmaceutical the right to develop drugs using small nucleic acid technology platforms such as Liver targeting GalNAc delivery at a number of designated targets, and to cooperate in the fields of cardiovascular, metabolic, and respiratory diseases; Dazzling Biotech authorized Haizheng Pharmaceutical to develop subsequent development and commercialization rights for a liver-targeted siRNA drug RGN6669 in the early preclinical development stage.
Share
Listen to the news
On November 13, Zhejiang Haizheng Pharmaceutical Co., Ltd. and Suzhou Xuanjing Biotechnology Co., Ltd. and its wholly-owned subsidiary Beijing Xuanjingrui Pharmaceutical Technology Co., Ltd. formally signed a small nucleic acid licensing cooperation agreement. Dazzling Biotech granted Haizheng Pharmaceutical the right to develop drugs using small nucleic acid technology platforms such as Liver targeting GalNAc delivery at a number of designated targets, and to cooperate in the fields of cardiovascular, metabolic, and respiratory diseases; Dazzling Biotech authorized Haizheng Pharmaceutical to develop subsequent development and commercialization rights for a liver-targeted siRNA drug RGN6669 in the early preclinical development stage.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending